Listed

Verrica Pharmaceuticals Inc.

VRCANasdaqCIK 1660334HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$5.9m, Q2 FY2026
Operating income−$13.1m, Q2 FY2026
Net income−$13.2m, Q2 FY2026
Verrica Pharmaceuticals Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m2.9Revenue, Q3 FY2023, three months to 2023-09-30$2.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figure2.0Revenue, Q4 FY2023, three months to 2023-12-31$2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-11, accession 0000950170-25-037172. Derived: 12-month figure less the 9-month figure.Report this figure3.8Revenue, Q1 FY2024, three months to 2024-03-31$3.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-13, accession 0000950170-25-070452.Report this figure5.2Revenue, Q2 FY2024, three months to 2024-06-30$5.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-12, accession 0000950170-25-107358.Report this figure(1.8)Revenue, Q3 FY2024, three months to 2024-09-30−$1.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figure0.3Revenue, Q4 FY2024, three months to 2024-12-31$344.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-11, accession 0000950170-25-037172. Derived: 12-month figure less the 9-month figure.Report this figure3.4Revenue, Q1 FY2025, three months to 2025-03-31$3.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-13, accession 0000950170-25-070452.Report this figure12.7Revenue, Q2 FY2025, three months to 2025-06-30$12.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-12, accession 0000950170-25-107358.Report this figure14.3Revenue, Q3 FY2025, three months to 2025-09-30$14.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure5.1Revenue, Q4 FY2025, three months to 2025-12-31$5.1m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-11, accession 0001660334-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure5.0Revenue, Q1 FY2026, three months to 2026-03-31$5.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure5.9Revenue, Q2 FY2026, three months to 2026-06-30$5.9m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure
Cost of revenue$m0.3Cost of revenue, Q3 FY2023, three months to 2023-09-30$300.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2023-11-09, accession 0000950170-23-061543.Report this figure0.2Cost of revenue, Q4 FY2023, three months to 2023-12-31$200.0k. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2025-03-11, accession 0000950170-25-037172. Derived: 12-month figure less the 9-month figure.Report this figure0.7Cost of revenue, Q1 FY2024, three months to 2024-03-31$700.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2024-05-13, accession 0000950170-24-058208.Report this figure0.7Cost of revenue, Q2 FY2024, three months to 2024-06-30$700.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2024-08-14, accession 0000950170-24-096669.Report this figure0.4Cost of revenue, Q3 FY2024, three months to 2024-09-30$400.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figure0.8Cost of revenue, Q4 FY2024, three months to 2024-12-31$800.0k. XBRL concept us-gaap:CostOfRevenue. 10-K filed 2025-03-11, accession 0000950170-25-037172. Derived: 12-month figure less the 9-month figure.Report this figure0.7Cost of revenue, Q1 FY2025, three months to 2025-03-31$700.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2025-05-13, accession 0000950170-25-070452.Report this figurenot reportednot reportednot reportednot reportednot reported
Research and development$m6.5Research and development, Q3 FY2023, three months to 2023-09-30$6.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figure5.3Research and development, Q4 FY2023, three months to 2023-12-31$5.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-11, accession 0000950170-25-037172. Derived: 12-month figure less the 9-month figure.Report this figure4.9Research and development, Q1 FY2024, three months to 2024-03-31$4.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0000950170-25-070452.Report this figure3.3Research and development, Q2 FY2024, three months to 2024-06-30$3.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-12, accession 0000950170-25-107358.Report this figure2.4Research and development, Q3 FY2024, three months to 2024-09-30$2.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure1.2Research and development, Q4 FY2024, three months to 2024-12-31$1.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-11, accession 0001660334-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure2.3Research and development, Q1 FY2025, three months to 2025-03-31$2.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure1.8Research and development, Q2 FY2025, three months to 2025-06-30$1.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure2.2Research and development, Q3 FY2025, three months to 2025-09-30$2.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure2.5Research and development, Q4 FY2025, three months to 2025-12-31$2.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-11, accession 0001660334-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure3.9Research and development, Q1 FY2026, three months to 2026-03-31$3.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure6.0Research and development, Q2 FY2026, three months to 2026-06-30$6.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure
Selling, general and administrative$m20.1Selling, general and administrative, Q3 FY2023, three months to 2023-09-30$20.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figure17.0Selling, general and administrative, Q4 FY2023, three months to 2023-12-31$17.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2025-03-11, accession 0000950170-25-037172. Derived: 12-month figure less the 9-month figure.Report this figure16.3Selling, general and administrative, Q1 FY2024, three months to 2024-03-31$16.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-05-13, accession 0000950170-25-070452.Report this figure16.5Selling, general and administrative, Q2 FY2024, three months to 2024-06-30$16.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-08-12, accession 0000950170-25-107358.Report this figure16.1Selling, general and administrative, Q3 FY2024, three months to 2024-09-30$16.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure9.9Selling, general and administrative, Q4 FY2024, three months to 2024-12-31$9.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-03-11, accession 0001660334-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure8.8Selling, general and administrative, Q1 FY2025, three months to 2025-03-31$8.8m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure8.9Selling, general and administrative, Q2 FY2025, three months to 2025-06-30$8.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure9.4Selling, general and administrative, Q3 FY2025, three months to 2025-09-30$9.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure8.1Selling, general and administrative, Q4 FY2025, three months to 2025-12-31$8.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-03-11, accession 0001660334-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure10.0Selling, general and administrative, Q1 FY2026, three months to 2026-03-31$10.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure10.3Selling, general and administrative, Q2 FY2026, three months to 2026-06-30$10.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure
Operating income$m(23.9)Operating income, Q3 FY2023, three months to 2023-09-30−$23.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figure(23.1)Operating income, Q4 FY2023, three months to 2023-12-31−$23.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-11, accession 0000950170-25-037172. Derived: 12-month figure less the 9-month figure.Report this figure(18.6)Operating income, Q1 FY2024, three months to 2024-03-31−$18.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0000950170-25-070452.Report this figure(15.2)Operating income, Q2 FY2024, three months to 2024-06-30−$15.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-12, accession 0000950170-25-107358.Report this figure(20.7)Operating income, Q3 FY2024, three months to 2024-09-30−$20.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure(11.4)Operating income, Q4 FY2024, three months to 2024-12-31−$11.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-11, accession 0001660334-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure(8.1)Operating income, Q1 FY2025, three months to 2025-03-31−$8.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure1.5Operating income, Q2 FY2025, three months to 2025-06-30$1.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure1.6Operating income, Q3 FY2025, three months to 2025-09-30$1.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure(7.2)Operating income, Q4 FY2025, three months to 2025-12-31−$7.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-11, accession 0001660334-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure(9.7)Operating income, Q1 FY2026, three months to 2026-03-31−$9.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure(13.1)Operating income, Q2 FY2026, three months to 2026-06-30−$13.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure
Interest expense$m1.7Interest expense, Q3 FY2023, three months to 2023-09-30$1.7m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-09, accession 0000950170-23-061543.Report this figure2.3Interest expense, Q4 FY2023, three months to 2023-12-31$2.3m. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-02-29, accession 0000950170-24-022659. Derived: 12-month figure less the 9-month figure.Report this figure2.3Interest expense, Q1 FY2024, three months to 2024-03-31$2.3m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-13, accession 0000950170-24-058208.Report this figure2.4Interest expense, Q2 FY2024, three months to 2024-06-30$2.4m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-08-14, accession 0000950170-24-096669.Report this figure2.4Interest expense, Q3 FY2024, three months to 2024-09-30$2.4m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure2.3Interest expense, Q4 FY2024, three months to 2024-12-31$2.3m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-11, accession 0001660334-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure2.2Interest expense, Q1 FY2025, three months to 2025-03-31$2.2m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure2.1Interest expense, Q2 FY2025, three months to 2025-06-30$2.1m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure2.1Interest expense, Q3 FY2025, three months to 2025-09-30$2.1m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure1.3Interest expense, Q4 FY2025, three months to 2025-12-31$1.3m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-11, accession 0001660334-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure0.2Interest expense, Q1 FY2026, three months to 2026-03-31$160.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure0.2Interest expense, Q2 FY2026, three months to 2026-06-30$164.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure
Net income$m(24.8)Net income, Q3 FY2023, three months to 2023-09-30−$24.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figure(24.6)Net income, Q4 FY2023, three months to 2023-12-31−$24.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-11, accession 0000950170-25-037172. Derived: 12-month figure less the 9-month figure.Report this figure(20.3)Net income, Q1 FY2024, three months to 2024-03-31−$20.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure(17.2)Net income, Q2 FY2024, three months to 2024-06-30−$17.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure(22.9)Net income, Q3 FY2024, three months to 2024-09-30−$22.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure(16.2)Net income, Q4 FY2024, three months to 2024-12-31−$16.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-11, accession 0001660334-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure(9.7)Net income, Q1 FY2025, three months to 2025-03-31−$9.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure0.2Net income, Q2 FY2025, three months to 2025-06-30$204.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure(0.3)Net income, Q3 FY2025, three months to 2025-09-30−$274.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure(8.1)Net income, Q4 FY2025, three months to 2025-12-31−$8.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-11, accession 0001660334-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure(9.7)Net income, Q1 FY2026, three months to 2026-03-31−$9.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure(13.2)Net income, Q2 FY2026, three months to 2026-06-30−$13.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure
Diluted EPS$ per share(0.54)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figurenot reported(0.44)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0000950170-25-070452.Report this figure(3.70)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$3.70 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-12, accession 0000950170-25-107358.Report this figure(4.88)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$4.88 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figurenot reported(1.03)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$1.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure0.02Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure(0.03)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figurenot reported(0.45)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure(0.62)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure
Basic EPS$ per share(0.54)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.54 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figurenot reported(0.44)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0000950170-25-070452.Report this figure(3.70)Basic EPS, Q2 FY2024, three months to 2024-06-30−$3.70 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-12, accession 0000950170-25-107358.Report this figure(4.88)Basic EPS, Q3 FY2024, three months to 2024-09-30−$4.88 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figurenot reported(1.03)Basic EPS, Q1 FY2025, three months to 2025-03-31−$1.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure0.02Basic EPS, Q2 FY2025, three months to 2025-06-30$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure(0.03)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figurenot reported(0.45)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure(0.62)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure

Balance sheet

Cash and equivalents$11.2m, Q2 FY2026
Long-term debt$0, FY2025
Shareholders' equity$4.3m, Q2 FY2026
Verrica Pharmaceuticals Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m84.3Cash and equivalents, Q3 FY2023, at 2023-09-30$84.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0000950170-23-061543.Report this figure69.5Cash and equivalents, FY2023, at 2023-12-31$69.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-11, accession 0000950170-25-037172.Report this figure48.9Cash and equivalents, Q1 FY2024, at 2024-03-31$48.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-13, accession 0000950170-24-058208.Report this figure31.9Cash and equivalents, Q2 FY2024, at 2024-06-30$31.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-14, accession 0000950170-24-096669.Report this figure23.0Cash and equivalents, Q3 FY2024, at 2024-09-30$23.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figure46.3Cash and equivalents, FY2024, at 2024-12-31$46.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-11, accession 0001660334-26-000008.Report this figure29.6Cash and equivalents, Q1 FY2025, at 2025-03-31$29.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure15.4Cash and equivalents, Q2 FY2025, at 2025-06-30$15.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure21.1Cash and equivalents, Q3 FY2025, at 2025-09-30$21.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure30.1Cash and equivalents, FY2025, at 2025-12-31$30.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure20.6Cash and equivalents, Q1 FY2026, at 2026-03-31$20.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure11.2Cash and equivalents, Q2 FY2026, at 2026-06-30$11.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure
Current assets$m91.7Current assets, Q3 FY2023, at 2023-09-30$91.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0000950170-23-061543.Report this figure77.5Current assets, FY2023, at 2023-12-31$77.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-11, accession 0000950170-25-037172.Report this figure61.4Current assets, Q1 FY2024, at 2024-03-31$61.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-13, accession 0000950170-24-058208.Report this figure47.3Current assets, Q2 FY2024, at 2024-06-30$47.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-14, accession 0000950170-24-096669.Report this figure28.2Current assets, Q3 FY2024, at 2024-09-30$28.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figure51.2Current assets, FY2024, at 2024-12-31$51.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-11, accession 0001660334-26-000008.Report this figure39.5Current assets, Q1 FY2025, at 2025-03-31$39.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0000950170-25-070452.Report this figure36.8Current assets, Q2 FY2025, at 2025-06-30$36.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-12, accession 0000950170-25-107358.Report this figure36.3Current assets, Q3 FY2025, at 2025-09-30$36.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure42.5Current assets, FY2025, at 2025-12-31$42.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure34.1Current assets, Q1 FY2026, at 2026-03-31$34.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure32.6Current assets, Q2 FY2026, at 2026-06-30$32.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure
Total assets$m97.1Total assets, Q3 FY2023, at 2023-09-30$97.1m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0000950170-23-061543.Report this figure81.6Total assets, FY2023, at 2023-12-31$81.6m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-11, accession 0000950170-25-037172.Report this figure66.3Total assets, Q1 FY2024, at 2024-03-31$66.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-13, accession 0000950170-24-058208.Report this figure52.0Total assets, Q2 FY2024, at 2024-06-30$52.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-14, accession 0000950170-24-096669.Report this figure32.9Total assets, Q3 FY2024, at 2024-09-30$32.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figure54.1Total assets, FY2024, at 2024-12-31$54.1m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-11, accession 0001660334-26-000008.Report this figure42.2Total assets, Q1 FY2025, at 2025-03-31$42.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0000950170-25-070452.Report this figure39.1Total assets, Q2 FY2025, at 2025-06-30$39.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-12, accession 0000950170-25-107358.Report this figure40.9Total assets, Q3 FY2025, at 2025-09-30$40.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure47.1Total assets, FY2025, at 2025-12-31$47.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure38.8Total assets, Q1 FY2026, at 2026-03-31$38.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure36.0Total assets, Q2 FY2026, at 2026-06-30$36.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure
Current liabilities$m11.4Current liabilities, Q3 FY2023, at 2023-09-30$11.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0000950170-23-061543.Report this figure17.0Current liabilities, FY2023, at 2023-12-31$17.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-11, accession 0000950170-25-037172.Report this figure19.4Current liabilities, Q1 FY2024, at 2024-03-31$19.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-13, accession 0000950170-24-058208.Report this figure20.1Current liabilities, Q2 FY2024, at 2024-06-30$20.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-14, accession 0000950170-24-096669.Report this figure21.0Current liabilities, Q3 FY2024, at 2024-09-30$21.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figure29.0Current liabilities, FY2024, at 2024-12-31$29.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-11, accession 0001660334-26-000008.Report this figure29.4Current liabilities, Q1 FY2025, at 2025-03-31$29.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0000950170-25-070452.Report this figure29.2Current liabilities, Q2 FY2025, at 2025-06-30$29.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-12, accession 0000950170-25-107358.Report this figure28.9Current liabilities, Q3 FY2025, at 2025-09-30$28.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure16.4Current liabilities, FY2025, at 2025-12-31$16.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure16.2Current liabilities, Q1 FY2026, at 2026-03-31$16.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure22.4Current liabilities, Q2 FY2026, at 2026-06-30$22.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure
Total liabilities$m54.8Total liabilities, Q3 FY2023, at 2023-09-30$54.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0000950170-23-061543.Report this figure61.8Total liabilities, FY2023, at 2023-12-31$61.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-11, accession 0000950170-25-037172.Report this figure64.8Total liabilities, Q1 FY2024, at 2024-03-31$64.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-13, accession 0000950170-24-058208.Report this figure65.3Total liabilities, Q2 FY2024, at 2024-06-30$65.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-14, accession 0000950170-24-096669.Report this figure67.0Total liabilities, Q3 FY2024, at 2024-09-30$67.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figure64.0Total liabilities, FY2024, at 2024-12-31$64.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-11, accession 0001660334-26-000008.Report this figure60.8Total liabilities, Q1 FY2025, at 2025-03-31$60.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0000950170-25-070452.Report this figure56.6Total liabilities, Q2 FY2025, at 2025-06-30$56.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-12, accession 0000950170-25-107358.Report this figure57.9Total liabilities, Q3 FY2025, at 2025-09-30$57.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure22.4Total liabilities, FY2025, at 2025-12-31$22.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure22.7Total liabilities, Q1 FY2026, at 2026-03-31$22.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure31.7Total liabilities, Q2 FY2026, at 2026-06-30$31.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure
Long-term debt$m42.4Long-term debt, Q3 FY2023, at 2023-09-30$42.4m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2023-11-09, accession 0000950170-23-061543.Report this figure42.9Long-term debt, FY2023, at 2023-12-31$42.9m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2025-03-11, accession 0000950170-25-037172.Report this figure42.8Long-term debt, Q1 FY2024, at 2024-03-31$42.8m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-05-13, accession 0000950170-24-058208.Report this figure42.8Long-term debt, Q2 FY2024, at 2024-06-30$42.8m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-08-14, accession 0000950170-24-096669.Report this figure43.3Long-term debt, Q3 FY2024, at 2024-09-30$43.3m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figure31.0Long-term debt, FY2024, at 2024-12-31$31.0m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2026-03-11, accession 0001660334-26-000008.Report this figure27.8Long-term debt, Q1 FY2025, at 2025-03-31$27.8m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-05-13, accession 0000950170-25-070452.Report this figure24.6Long-term debt, Q2 FY2025, at 2025-06-30$24.6m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-08-12, accession 0000950170-25-107358.Report this figure21.6Long-term debt, Q3 FY2025, at 2025-09-30$21.6m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure0.0Long-term debt, FY2025, at 2025-12-31$0. XBRL concept us-gaap:LongTermDebt. 10-K filed 2026-03-11, accession 0001660334-26-000008.Report this figurenot reportednot reported
Current portion of debt$mnot reported0.0Current portion of debt, FY2023, at 2023-12-31$0. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2025-03-11, accession 0000950170-25-037172.Report this figurenot reportednot reportednot reported12.9Current portion of debt, FY2024, at 2024-12-31$12.9m. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2026-03-11, accession 0001660334-26-000008.Report this figure12.8Current portion of debt, Q1 FY2025, at 2025-03-31$12.8m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2025-05-13, accession 0000950170-25-070452.Report this figure12.7Current portion of debt, Q2 FY2025, at 2025-06-30$12.7m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2025-08-12, accession 0000950170-25-107358.Report this figure12.5Current portion of debt, Q3 FY2025, at 2025-09-30$12.5m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure0.0Current portion of debt, FY2025, at 2025-12-31$0. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2026-03-11, accession 0001660334-26-000008.Report this figurenot reportednot reported
Short-term borrowings$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m42.3Shareholders' equity, Q3 FY2023, at 2023-09-30$42.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figure19.8Shareholders' equity, FY2023, at 2023-12-31$19.8m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-11, accession 0001660334-26-000008.Report this figure1.5Shareholders' equity, Q1 FY2024, at 2024-03-31$1.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure(13.3)Shareholders' equity, Q2 FY2024, at 2024-06-30−$13.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure(34.1)Shareholders' equity, Q3 FY2024, at 2024-09-30−$34.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure(9.9)Shareholders' equity, FY2024, at 2024-12-31−$9.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure(18.6)Shareholders' equity, Q1 FY2025, at 2025-03-31−$18.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure(17.5)Shareholders' equity, Q2 FY2025, at 2025-06-30−$17.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure(17.0)Shareholders' equity, Q3 FY2025, at 2025-09-30−$17.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure24.7Shareholders' equity, FY2025, at 2025-12-31$24.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure16.1Shareholders' equity, Q1 FY2026, at 2026-03-31$16.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure4.3Shareholders' equity, Q2 FY2026, at 2026-06-30$4.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure

Cash flow

Operating cash flow−$9.3m, Q2 FY2026
Capital expenditure$0, Q4 FY2025
Verrica Pharmaceuticals Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(14.8)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$14.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-05, accession 0000950170-24-120982. Derived: 9-month figure less the 6-month figure.Report this figure(14.5)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$14.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-11, accession 0000950170-25-037172. Derived: 12-month figure less the 9-month figure.Report this figure(19.9)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$19.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0000950170-25-070452.Report this figure(16.4)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$16.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-12, accession 0000950170-25-107358. Derived: 6-month figure less the 3-month figure.Report this figure(8.6)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$8.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001660334-25-000006. Derived: 9-month figure less the 6-month figure.Report this figure(16.1)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$16.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-11, accession 0001660334-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure(12.7)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$12.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure(10.0)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$10.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001660334-26-000025. Derived: 6-month figure less the 3-month figure.Report this figure9.7Operating cash flow, Q3 FY2025, three months to 2025-09-30$9.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001660334-25-000006. Derived: 9-month figure less the 6-month figure.Report this figure(4.6)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$4.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-11, accession 0001660334-26-000008. Derived: 12-month figure less the 9-month figure.Report this figure(9.2)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$9.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure(9.3)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$9.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001660334-26-000025. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.1Capital expenditure, Q3 FY2023, three months to 2023-09-30$65.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-05, accession 0000950170-24-120982. Derived: 9-month figure less the 6-month figure.Report this figure0.2Capital expenditure, Q4 FY2023, three months to 2023-12-31$227.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-11, accession 0000950170-25-037172. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-05-13, accession 0000950170-24-058208.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$11.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-12, accession 0000950170-25-107358. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$16.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001660334-25-000006. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-11, accession 0001660334-26-000008. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001660334-25-000006. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-11, accession 0001660334-26-000008. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported

Shares

Diluted shares (weighted)21.31m, Q2 FY2026
Verrica Pharmaceuticals Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares40.3Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3040,321,639 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0000950170-23-061543.Report this figure43.0Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3143,023,379 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-13, accession 0000950170-24-058208.Report this figure45.9Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3045,916,867 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-14, accession 0000950170-24-096669.Report this figure46.1Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3046,073,932 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-05, accession 0000950170-24-120982.Report this figure46.5Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3146,483,669 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0000950170-25-070452.Report this figure4.7Diluted shares (weighted), Q2 FY2024, three months to 2024-06-304,650,227 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-12, accession 0000950170-25-107358.Report this figure4.7Diluted shares (weighted), Q3 FY2024, three months to 2024-09-304,680,543 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure9.5Diluted shares (weighted), Q1 FY2025, three months to 2025-03-319,483,734 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure9.5Diluted shares (weighted), Q2 FY2025, three months to 2025-06-309,490,600 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure9.5Diluted shares (weighted), Q3 FY2025, three months to 2025-09-309,490,083 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001660334-25-000006.Report this figure21.3Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3121,305,025 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001660334-26-000014.Report this figure21.3Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3021,305,025 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure

Shares outstanding: 17.18mShares outstanding, period not labelled, at 2026-07-3117,178,786 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001660334-26-000025.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.